Lonza Group AG stock (CH0013841017): Swiss CDMO trades softer after Q1 update

Lonza Group AG shares eased on the SIX Swiss Exchange after the latest quarterly update, with the Swiss CDMO stock trading slightly lower in a muted session for the domestic market.

Lonza Group AG shares traded slightly weaker on the SIX Swiss Exchange on 05/28/2026, with the Swiss contract development and manufacturing organization (CDMO) changing hands around 493.20 CHF at midday, down roughly 0.7 percent in a softer session for the Swiss equity market, according to Lonza Group and Swiss exchange data as reported by ad-hoc-news.de on 05/28/2026 and finanzen.ch on 05/28/2026.

The stock remains part of the Swiss blue-chip universe, and its move came in the wake of the company’s recent quarterly business update, which investors digested against the broader backdrop of the Swiss Market Index trading near 13,484 points at midday on 05/28/2026, as noted by finanzen.ch on 05/28/2026.

The stock traded at approximately 493.20 CHF on 05/28/2026 on the SIX Swiss Exchange, according to finanzen.ch as of 05/28/2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Lonza Group
• Sector/industry: Contract development and manufacturing for pharmaceuticals and biotech
• Headquarters/country: Basel, Switzerland
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Custom manufacturing of active pharmaceutical ingredients, biologics and cell-and-gene therapies, as well as related development services
• Home exchange/listing venue: SIX Swiss Exchange (LONN)
• Trading currency: CHF

Lonza Group AG: core business model

Lonza Group AG focuses on providing outsourced development and manufacturing services for pharmaceutical and biotechnology customers worldwide, generating revenue mainly from long-term contracts to produce complex active ingredients, biologics and advanced therapies across multiple therapeutic areas.

Valuation metrics and multiples for Lonza Group AG

Investors assessing Lonza Group AG on 05/29/2026 typically look at core valuation ratios such as price-earnings and enterprise-value-to-EBITDA, which reflect expectations for the Swiss CDMO’s long-term growth and margin profile relative to other healthcare names in Switzerland and abroad. Market data providers including MarketScreener and other financial portals track these metrics based on the company’s most recently reported earnings and updated consensus forecasts during 2026.

Because Lonza operates a capital-intensive manufacturing footprint and often enters multi-year supply agreements with large pharmaceutical groups, the market also pays attention to cash flow-based metrics and balance-sheet indicators alongside P/E and EV/EBITDA when comparing the stock with other European life-science suppliers, as highlighted in current 2026 market commentary on Swiss healthcare stocks.

Conclusion

The slight pullback in Lonza Group AG’s share price on the SIX Swiss Exchange after the most recent quarterly update underscores how closely the Swiss market tracks operational signals from key healthcare suppliers. Against this backdrop, valuation metrics such as P/E and EV/EBITDA remain important tools for investors comparing Lonza with other European CDMOs and life-science peers. The coming quarters’ execution on contracts, capacity utilization and margin progression will likely be central factors for how the stock is rated within the Swiss blue-chip universe.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.